HRP20240065T1 - Hemostatički pripravci - Google Patents
Hemostatički pripravci Download PDFInfo
- Publication number
- HRP20240065T1 HRP20240065T1 HRP20240065TT HRP20240065T HRP20240065T1 HR P20240065 T1 HRP20240065 T1 HR P20240065T1 HR P20240065T T HRP20240065T T HR P20240065TT HR P20240065 T HRP20240065 T HR P20240065T HR P20240065 T1 HRP20240065 T1 HR P20240065T1
- Authority
- HR
- Croatia
- Prior art keywords
- fibrinogen
- amino acid
- acid residues
- optionally
- binding
- Prior art date
Links
- 229940030225 antihemorrhagics Drugs 0.000 title claims 7
- 239000000203 mixture Substances 0.000 title claims 7
- 230000000025 haemostatic effect Effects 0.000 title 1
- 125000000539 amino acid group Chemical group 0.000 claims 25
- 102000008946 Fibrinogen Human genes 0.000 claims 24
- 108010049003 Fibrinogen Proteins 0.000 claims 24
- 229940012952 fibrinogen Drugs 0.000 claims 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 15
- VWJLJHZPMZGDDV-HOCDWTQPSA-N (4s)-4-amino-5-[[(2s)-1-[[(2s,3s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CCC(O)=O)C1=CN=CN1 VWJLJHZPMZGDDV-HOCDWTQPSA-N 0.000 claims 12
- 239000000969 carrier Substances 0.000 claims 7
- 239000007788 liquid Substances 0.000 claims 7
- 239000002874 hemostatic agent Substances 0.000 claims 6
- 239000002245 particle Substances 0.000 claims 6
- 150000001413 amino acids Chemical group 0.000 claims 5
- 230000001954 sterilising effect Effects 0.000 claims 5
- 238000004659 sterilization and disinfection Methods 0.000 claims 5
- 230000002439 hemostatic effect Effects 0.000 claims 4
- 239000007791 liquid phase Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 150000004676 glycans Chemical class 0.000 claims 3
- 229920001282 polysaccharide Polymers 0.000 claims 3
- 239000005017 polysaccharide Substances 0.000 claims 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 2
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 2
- 229940072056 alginate Drugs 0.000 claims 2
- 229920000615 alginic acid Polymers 0.000 claims 2
- 235000010443 alginic acid Nutrition 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- 230000023597 hemostasis Effects 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 1
- 229920002201 Oxidized cellulose Polymers 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000009697 arginine Nutrition 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 235000004554 glutamine Nutrition 0.000 claims 1
- 229960003104 ornithine Drugs 0.000 claims 1
- 229940107304 oxidized cellulose Drugs 0.000 claims 1
- 235000013808 oxidized starch Nutrition 0.000 claims 1
- 239000001254 oxidized starch Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0052—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Claims (15)
1. Sterilni, tekući hemostatski pripravak spreman za uporabu, koji sadrži:
topljivo hemostatsko sredstvo koje sadrži mnoštvo nosača i mnoštvo peptida koji vežu fibrinogen imobiliziranih na svaki nosač, pri čemu svaki nosač hemostatskog sredstva sadrži razgranatu jezgru na koju su peptidi koji vežu fibrinogen odvojeno kovalentno vezani;
biokompatibilnu tekućinu; i
čestice biokompatibilnog umreženog polisaharida pogodnog za uporabu u hemostazi i koje su netopljive u biokompatibilnoj tekućini;
pri čemu razgranata jezgra sadrži:
od dva do deset multifunkcionalnih aminokiselinskih ostataka, pri čemu je svaki peptid koji veže fibrinogen odvojeno kovalentno vezan na multifunkcionalni aminokiselinski ostatak razgranate jezgre;
mnoštvo višenamjenskih aminokiselinskih ostataka, pri čemu su jedan ili više peptida koji vežu fibrinogen odvojeno kovalentno vezani za svaki od najmanje dva susjedna višenamjenska aminokiselinska ostatka razgranate jezgre;
mnoštvo višenamjenskih aminokiselinskih ostataka, pri čemu su dva ili više peptida koji vežu fibrinogen odvojeno kovalentno vezani na najmanje jedan od višenamjenskih aminokiselinskih ostataka razgranate jezgre; ili
mnoštvo multifunkcionalnih aminokiselinskih ostataka, pri čemu su dva ili više multifunkcionalnih aminokiselinskih ostataka kovalentno povezani preko bočnog lanca susjednog multifunkcionalnog aminokiselinskog ostatka;
pri čemu višefunkcionalni aminokiselinski ostaci sadrže tri- ili tetra-funkcionalne aminokiselinske ostatke, ili
tri- i tetra-funkcionalne aminokiselinske ostatke.
2. Pripravak prema zahtjevu 1, naznačen time što mnoštvo multifunkcionalnih aminokiselinskih ostataka sadrži lizin, ornitin, arginin, asparaginsku kiselinu, glutaminsku kiselinu, asparagin, glutamin, ili ostatak cisteina.
3. Pripravak prema zahtjevu 1, naznačen time što je svaki peptid koji veže fibrinogen vezan za razgranatu jezgru pomoću nepeptidnog poveznika, izborno pri čemu poveznik sadrži ravno-lančani poveznik, poželjno ravno-lančanu alkilnu skupinu, i izborno pri čemu poveznik sadrži -NH(CH2)nCO-, gdje je n 1-10.
4. Pripravak prema bilo kojem prethodnom zahtjevu, naznačen time što hemostatsko sredstvo sadrži peptide koji vežu fibrinogen različite sekvence, izborno pri čemu mnoštvo nosača sadrži prvo mnoštvo nosača i drugo mnoštvo nosača, i gdje su peptidi koji vežu fibrinogen vezani na prvu množinu nosača različitog slijeda od peptida koji vežu fibrinogen vezanih na drugu množinu nosača, izborno gdje svaki nosač ima peptide koji vežu fibrinogen različitog slijeda vezane na njega, i izborno gdje peptidi koji vežu fibrinogen različitog slijeda imaju različitu selektivnost vezanja na rupu 'a' preko rupe 'b' fibrinogena.
5. Pripravak prema zahtjevu 4, naznačen time što peptidi koji vežu fibrinogen od različite sekvence sadrže prvi peptid koji veže fibrinogen koji se preferencijalno veže na rupu 'a' fibrinogena preko rupe 'b' fibrinogena, i drugi peptid koji veže fibrinogen koji se veže s većom selektivnošću vezanja na rupu 'a' fibrinogena preko rupe 'b' fibrinogena od prvog peptida koji veže fibrinogen, izborno pri čemu prvi peptid koji veže fibrinogen sadrži aminokiselinsku sekvencu GPRP- (SEQ ID NO: 1) na njegov amino-terminalni kraj, i izborno pri čemu drugi peptid koji veže fibrinogen sadrži aminokiselinsku sekvencu -APFPRPG (SEQ ID NO: 14) na svom karboksi-terminalnom kraju.
6. Pripravak prema zahtjevu 4, naznačen time što peptidi koji vežu fibrinogen od različite sekvence sadrže prvi peptid koji veže fibrinogen koji se preferencijalno veže na rupu 'a' fibrinogena preko rupe 'b' fibrinogena, i drugi peptid koji veže fibrinogen koji se veže preferirano na rupu 'b' fibrinogena preko rupe 'a' fibrinogena, izborno pri čemu prvi peptid koji veže fibrinogen sadrži aminokiselinsku sekvencu GPRP-(SEQ ID NO: 1) na svom amino-terminalnom kraju, i izborno pri čemu drugi peptid koji veže fibrinogen sadrži aminokiselinsku sekvencu GHRP- (SEQ ID NO: 10), poželjno aminokiselinsku sekvencu GHRPY- (SEQ ID NO: 11), na svom amino terminalnom kraju.
7. Pripravak prema bilo kojem prethodnom zahtjevu, naznačen time što je biokompatibilna tekućina vodena otopina, i izborno pri čemu je vodena otopina slana otopina.
8. Pripravak prema bilo kojem prethodnom zahtjevu, naznačen time što polisaharid sadrži glikozaminoglikan, oksidiranu celulozu, kitozan, hitin, alginat, oksidirani alginat, ili oksidirani škrob, i izborno pri čemu glikozaminoglikan sadrži hijaluronsku kiselinu.
9. Pripravak prema bilo kojem prethodnom zahtjevu, naznačen time što čestice sadrže umrežene granule hijaluronske kiseline, pri čemu većina granula ima promjer u rasponu od 100-1500 µm u djelomično ili potpuno hidratiziranom obliku.
10. Pripravak prema bilo kojem prethodnom zahtjevu, naznačen time što je pripravak proziran.
11. Pripravak prema bilo kojem prethodnom zahtjevu, naznačen time što se koristi kao lijek i izborno za uporabu u liječenju krvarenja ili u liječenju rane.
12. Postupak za izradu sterilnog, spremnog za uporabu, tekućeg hemostatskog pripravka, koji sadrži:
miješanje zajedno biokompatibilne tekućine, topljivog hemostatskog sredstva, i čestica biokompatibilnog umreženog polisaharida prikladnog za uporabu u hemostazi i koji su netopljivi u biokompatibilnoj tekućini, pri čemu topivo hemostatsko sredstvo sadrži mnoštvo nosača i mnoštvo peptida koji vežu fibrinogen imobiliziran na svaki nosač, pri čemu svaki nosač hemostatskog sredstva sadrži razgranatu jezgru na koju su peptidi koji vežu fibrinogen odvojeno kovalentno vezani; i
steriliziranje pripravka;
pri čemu razgranata jezgra sadrži:
od dva do deset multifunkcionalnih aminokiselinskih ostataka, pri čemu je svaki peptid koji veže fibrinogen odvojeno kovalentno vezan na multifunkcionalni aminokiselinski ostatak razgranate jezgre;
mnoštvo višenamjenskih aminokiselinskih ostataka, pri čemu su jedan ili više peptida koji vežu fibrinogen zasebno kovalentno vezani za svaki od najmanje dva susjedna višenamjenska aminokiselinska ostatka razgranate jezgre;
mnoštvo višenamjenskih aminokiselinskih ostataka, pri čemu su dva ili više peptida koji vežu fibrinogen odvojeno kovalentno vezani na najmanje jedan od višenamjenskih aminokiselinskih ostataka razgranate jezgre; ili
mnoštvo multifunkcionalnih aminokiselinskih ostataka, pri čemu su dva ili više multifunkcionalnih aminokiselinskih ostataka kovalentno povezani preko bočnog lanca susjednog multifunkcionalnog aminokiselinskog ostatka;
pri čemu višefunkcionalni aminokiselinski ostaci sadrže tri- ili tetra-funkcionalne aminokiselinske ostatke, ili
tri- i tetra- funkcionalne aminokiselinske ostatke.
13. Pripravak prema zahtjevu 1, naznačen time što je hemostatski pripravak steriliziran sterilizacijom parom, ili sterilizacijom suhom toplinom, ili postupak prema zahtjevu 12, pri čemu je pripravak steriliziran sterilizacijom parom, ili sterilizacijom suhom toplinom.
14. Pripravak prema zahtjevu 1 ili 13, naznačen time što biokompatibilna tekućina osigurava kontinuiranu tekuću fazu, i čestice polimera su uglavnom homogeno raspršene kroz tekuću fazu, ili postupak prema zahtjevu 12 ili 13, pri čemu se tekućina, sredstvo i čestice miješaju pod uvjetima koji su učinkoviti za formiranje kontinuirane tekuće faze koja sadrži čestice uglavnom homogeno raspršene kroz tekuću fazu, čime se formira suštinski homogeni hemostatski pripravak.
15. Postupak prema bilo kojem od zahtjeva 12 do 14, koji nadalje sadrži centrifugiranje mješavine za uklanjanje mjehurića zraka iz mješavine.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1508024.5A GB201508024D0 (en) | 2015-05-11 | 2015-05-11 | Haemostatic compositions |
| PCT/GB2016/051346 WO2016181137A1 (en) | 2015-05-11 | 2016-05-11 | Haemostatic compositions |
| EP16723460.8A EP3294353B1 (en) | 2015-05-11 | 2016-05-11 | Haemostatic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240065T1 true HRP20240065T1 (hr) | 2024-03-29 |
Family
ID=53489436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240065TT HRP20240065T1 (hr) | 2015-05-11 | 2016-05-11 | Hemostatički pripravci |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11246958B2 (hr) |
| EP (1) | EP3294353B1 (hr) |
| JP (1) | JP6877360B2 (hr) |
| KR (1) | KR102645212B1 (hr) |
| CN (1) | CN107592814B (hr) |
| AU (1) | AU2016261108B2 (hr) |
| BR (1) | BR112017024162A2 (hr) |
| CA (1) | CA2983798A1 (hr) |
| GB (1) | GB201508024D0 (hr) |
| HR (1) | HRP20240065T1 (hr) |
| IL (1) | IL255579A (hr) |
| MX (1) | MX2017014418A (hr) |
| PH (1) | PH12017501946A1 (hr) |
| RU (1) | RU2744694C2 (hr) |
| WO (1) | WO2016181137A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE544460C2 (en) * | 2019-12-18 | 2022-06-07 | Amferia Ab | Improved wound care device |
| KR20230099838A (ko) | 2021-12-28 | 2023-07-05 | 인천대학교 산학협력단 | 가교 활성 지혈제 및 이의 용도 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE426902B (sv) * | 1980-05-23 | 1983-02-21 | Einar Sjolander | Etbart holje samt sett for dess framstellning |
| SE9101853D0 (sv) * | 1991-06-17 | 1991-06-17 | Jonas Wadstroem | Improved tissue ashesive |
| US5783663A (en) * | 1998-01-23 | 1998-07-21 | Bayer Corporation | Peptide ligands for affinity purification of fibrinogen |
| MXPA01002898A (es) | 1998-09-21 | 2002-06-04 | Genetics Inst | Metodos de modulacion descendente de la respuesta inmune a proteinas terapeuticas. |
| FR2813080B1 (fr) * | 2000-08-17 | 2002-11-29 | Stago Diagnostica | Peptides anti-heparine |
| CA2447383A1 (en) * | 2001-06-29 | 2003-01-09 | Biovitrum Ab | Process for bulk autoclaving |
| CN101675991A (zh) * | 2001-12-21 | 2010-03-24 | 诺和诺德医疗保健公司 | 因子ⅶ多肽的液体组合物 |
| US20040101546A1 (en) | 2002-11-26 | 2004-05-27 | Gorman Anne Jessica | Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents |
| CA2530032C (en) | 2003-06-16 | 2015-11-24 | Loma Linda University Medical Center | Deployable multifunctional hemostatic agent |
| GB0323378D0 (en) * | 2003-10-07 | 2003-11-05 | Univ Leicester | Therapeutic agent |
| US7431915B2 (en) | 2003-10-31 | 2008-10-07 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| US7842667B2 (en) * | 2003-12-22 | 2010-11-30 | Regentis Biomaterials Ltd. | Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same |
| EP2289567A3 (en) * | 2003-12-22 | 2011-06-22 | Regentis Biomaterials Ltd. | Matrix comprising naturally-occurring crosslinked protein backbone |
| US8124120B2 (en) * | 2003-12-22 | 2012-02-28 | Anika Therapeutics, Inc. | Crosslinked hyaluronic acid compositions for tissue augmentation |
| CA2571981C (en) | 2004-07-09 | 2014-12-30 | Ferrosan A/S | Haemostatic composition comprising hyaluronic acid |
| JP2008507362A (ja) | 2004-07-22 | 2008-03-13 | ヘモ ナノサイエンス リミテッド ライアビリティ カンパニー | 過剰な出血を処置するための組成物および方法 |
| GB0516091D0 (en) * | 2005-08-04 | 2005-09-14 | Haemostatix Ltd | Therapeutic agent |
| GB0623607D0 (en) | 2006-11-27 | 2007-01-03 | Haemostatix Ltd | Tissue adhesive |
| JP6084770B2 (ja) * | 2008-06-26 | 2017-02-22 | プロリンクス エルエルシー | 制御された薬剤放出速度を有するプロドラッグ及び薬剤−高分子のコンジュゲート |
| US20100021527A1 (en) | 2008-07-25 | 2010-01-28 | Chunlin Yang | Collagen-related peptides and uses thereof and hemostatic foam substrates |
| WO2011006069A1 (en) * | 2009-07-09 | 2011-01-13 | Georgia Tech Research Corporation | Peptides for binding fibrinogen and fibrin |
| US20110171310A1 (en) * | 2010-01-13 | 2011-07-14 | Allergan Industrie, Sas | Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use |
| GB201101740D0 (en) * | 2011-02-01 | 2011-03-16 | Haemostatix Ltd | Therapeutic agents with improved fibrinogen binding |
| CN103443117B (zh) * | 2011-04-29 | 2017-05-17 | 凯希特许有限公司 | 用于治疗因子在伤口环境中的结合的适体改性的聚合材料 |
| MX356185B (es) * | 2011-10-11 | 2018-05-17 | Baxter Int | Composiciones hemostaticas. |
| WO2013060769A2 (en) * | 2011-10-27 | 2013-05-02 | Baxter International Inc. | Hemostatic compositions |
| MX2014007500A (es) * | 2011-12-20 | 2014-07-28 | Pfizer | Procesos mejorados para preparar conjugados y enlazadores de peptido. |
| GB201201751D0 (en) * | 2012-02-01 | 2012-03-14 | Haemostatix Ltd | Haemostatic wound dressing |
| JP6322192B2 (ja) | 2013-07-08 | 2018-05-09 | デンカ株式会社 | コアシェル型架橋ヒアルロン酸ゲル粒子、その製造方法及び医用材料 |
| GB201400292D0 (en) * | 2014-01-08 | 2014-02-26 | Haemostatix Ltd | Peptide dendrimers and agents |
| CN104398287A (zh) * | 2014-11-27 | 2015-03-11 | 张汉桥 | 医用微创伤口止血固定带 |
-
2015
- 2015-05-11 GB GBGB1508024.5A patent/GB201508024D0/en not_active Ceased
-
2016
- 2016-05-11 KR KR1020177034020A patent/KR102645212B1/ko active IP Right Grant
- 2016-05-11 AU AU2016261108A patent/AU2016261108B2/en active Active
- 2016-05-11 BR BR112017024162A patent/BR112017024162A2/pt not_active Application Discontinuation
- 2016-05-11 JP JP2017558001A patent/JP6877360B2/ja active Active
- 2016-05-11 MX MX2017014418A patent/MX2017014418A/es unknown
- 2016-05-11 HR HRP20240065TT patent/HRP20240065T1/hr unknown
- 2016-05-11 US US15/572,915 patent/US11246958B2/en active Active
- 2016-05-11 CA CA2983798A patent/CA2983798A1/en active Pending
- 2016-05-11 WO PCT/GB2016/051346 patent/WO2016181137A1/en active Application Filing
- 2016-05-11 CN CN201680027393.2A patent/CN107592814B/zh active Active
- 2016-05-11 RU RU2017139789A patent/RU2744694C2/ru active
- 2016-05-11 EP EP16723460.8A patent/EP3294353B1/en active Active
-
2017
- 2017-10-25 PH PH12017501946A patent/PH12017501946A1/en unknown
- 2017-11-09 IL IL255579A patent/IL255579A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180154038A1 (en) | 2018-06-07 |
| RU2017139789A3 (hr) | 2019-07-29 |
| KR20180006390A (ko) | 2018-01-17 |
| CA2983798A1 (en) | 2016-11-17 |
| PH12017501946A1 (en) | 2018-03-19 |
| IL255579A (en) | 2018-01-31 |
| KR102645212B1 (ko) | 2024-03-07 |
| RU2744694C2 (ru) | 2021-03-15 |
| RU2017139789A (ru) | 2019-06-11 |
| BR112017024162A2 (pt) | 2018-07-17 |
| AU2016261108A1 (en) | 2017-11-16 |
| EP3294353A1 (en) | 2018-03-21 |
| CN107592814A (zh) | 2018-01-16 |
| CN107592814B (zh) | 2021-12-03 |
| JP6877360B2 (ja) | 2021-05-26 |
| EP3294353B1 (en) | 2023-10-25 |
| MX2017014418A (es) | 2018-03-02 |
| JP2018515216A (ja) | 2018-06-14 |
| US11246958B2 (en) | 2022-02-15 |
| WO2016181137A1 (en) | 2016-11-17 |
| GB201508024D0 (en) | 2015-06-24 |
| AU2016261108B2 (en) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Han et al. | Biofilm-inspired adhesive and antibacterial hydrogel with tough tissue integration performance for sealing hemostasis and wound healing | |
| US9717820B2 (en) | Procoagulant peptides and their derivatives and uses therefor | |
| HRP20231496T1 (hr) | Cistein proteaza | |
| Zhu et al. | Calcium ion–exchange cross-linked porous starch microparticles with improved hemostatic properties | |
| HRP20240065T1 (hr) | Hemostatički pripravci | |
| CN106928346A (zh) | 来自血液的间‑α抑制物蛋白的制备和组合物 | |
| RU2015126551A (ru) | Способ очистки лечебных белков | |
| RU2016104651A (ru) | Устойчивые к протеазам пептидные лиганды | |
| RU2016130448A (ru) | Пептидные дендримеры, содержащие фибриноген-связывающие пептиды | |
| RU2015146739A (ru) | Комплексы типа сахаридная цепочка-полипептид | |
| JP2015516189A5 (hr) | ||
| AU2016281477A1 (en) | Broad-spectrum anti-infective peptides | |
| CN107574217B (zh) | 一种纳米级胶原蛋白的提纯方法 | |
| CN102304281A (zh) | 聚氨酯多孔膜及其制备方法和应用 | |
| EP3315508A1 (en) | Polypeptide compound and preparation method and use thereof | |
| CN106474524A (zh) | 一种可降解淀粉止血海绵及其制备方法 | |
| RU2019107806A (ru) | Композиция для гемостаза, включающая сшивающую матрицу производного гиалуроновой кислоты | |
| JP6496484B2 (ja) | 創傷治癒剤 | |
| IL296230A (en) | preparations to stop bleeding | |
| RU2016129827A (ru) | Состав fgf-18 в ксилоглюкановых гелях | |
| Hassabo et al. | Extraction, structural properties, and applications of alginic acid | |
| CN107915771A (zh) | 一种多肽止血材料 | |
| CN103130872A (zh) | 吸附剂、固相载体及精制方法 | |
| CN104762357B (zh) | 马面鲀鱼皮锌螯合肽制备方法 | |
| JP2019163212A (ja) | スフェロイド形成促進剤の濃縮方法および精製方法。 |